Telix Pharmaceuticals doses first U.S. Pixclara patients

• The company officially commenced the U.S. commercial availability of its FDA-approved glioma imaging drug.
• Following the operational rollout, the company's shares traded lower at A$15.41.
• The launch establishes the foundation for an ongoing Phase 3 study evaluating an expanded diagnosis indication.

Telix Pharmaceuticals (NASDAQ:TLX) commenced U.S. distribution of its brain cancer imaging drug Pixclara with its first patient doses.

The agent uses positron emission tomography to help doctors distinguish recurrent glioma from standard treatment-related changes.

Manufacturing partner PharmaLogic is actively supplying finished unit doses directly to the United States clinical market.

The label warns of possible false imaging interpretations and cumulative radiation exposure linked to increased cancer risk.

The company stated it expects a Phase 3 study to evaluate brain metastases expansion.

The commercial distribution marks a progression of the company's diagnostic imaging portfolio within the neuro-oncology sector.

The launch follows a recent strategic partnership with ITM to expand the company's global radiopharmaceutical footprint.